Telix Pharmaceuticals Highlights $1B Revenue Track, Pixclara Resubmission, PSMA Growth at Oppenheimer Conf. [Yahoo! Finance]
Telix Pharmaceuticals Limited - American Depositary Shares (TLX)
Company Research
Source: Yahoo! Finance
franchise, operates in 26 countries, and is internally funding R&D (~$300 million) while vertically integrating commercial teams and in-house manufacturing including a U.S. nuclear pharmacy network. Telix is executing a two-track commercial strategy for PSMA prostate imaging—using Illuccix to win commercial contracts and the reimbursed lifecycle product Gozellix (longer shelf life, cyclotron production) to limit price erosion—and its BiPASS study could materially expand the PSMA PET market by reducing unnecessary biopsies. Regulatory and pipeline progress: Telix says Pixclara will be resubmitted imminently with Zircaix to follow in the coming months (Zircaix expected to launch this year), while therapeutics advance with TLX591 moving into randomized Phase III ex-U.S. and a LUTEON renal Phase III poised to start. Interested in Telix Pharmaceuticals Limited? Here are five stocks we like better. Telix Pharmaceuticals (NASDAQ:TLX) outlined its commercial imaging franchise, regulat
Show less
Read more
Impact Snapshot
Event Time:
TLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TLX alerts
High impacting Telix Pharmaceuticals Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
TLX
News
- Investor Education WebinarGlobeNewswire
- Investor Education WebinarPR Newswire
- Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET ImagingGlobeNewswire
- 1 Basically Unknown Stock That Could Turn Cancer-Imaging Breakthroughs Into Generational Wealth [Yahoo! Finance]Yahoo! Finance
- Telix Pharmaceuticals (NASDAQ:TLX) had its "buy" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
TLX
Sec Filings
- 2/20/26 - Form F-3ASR
- 2/20/26 - Form 20-F
- 2/19/26 - Form 6-K
- TLX's page on the SEC website